Anawalt B D, Bebb R A, Matsumoto A M, Groome N P, Illingworth P J, McNeilly A S, Bremner W J
Department of Veterans Affairs Medical Center, Seattle, Washington, USA.
J Clin Endocrinol Metab. 1996 Sep;81(9):3341-5. doi: 10.1210/jcem.81.9.8784094.
We used a recently developed ELISA format to test the hypothesis that inhibin B is the physiologically active form of inhibin in men. We measured and compared inhibin A, inhibin B, and pro-alpha-C-related immunoreactive peptides (pro-alpha-C-RI) in normal men before and after perturbations of their gonadotropin levels and baseline values in normal men and men with various disturbances of the hypothalamic-pituitary-testicular axis including men with idiopathic hypogonadotropic hypogonadism, infertile men with elevated FSH, men with Klinefelter's syndrome, and orchidectomized men. Mean serum inhibin concentrations were significantly higher in normal men than untreated men with idiopathic hypogonadotropic hypogonadism, infertile men with elevated FSH, untreated men with Klinefelter's syndrome, and orchidectomized men (187 +/- 28 vs 45 +/- 11, 37 +/- 6, 11 +/- 3, and < or = 10 pg/mL, respectively; P < 0.05). Inhibin B levels were below the limit of detection in all of the orchidectomized men. Pro-alpha-C-RI levels were detectable in all men studied including the orchidectomized men, and no significant differences in the pro-alpha-C-RI levels were noted between the normal men and men with various testicular diseases were noted except that orchidectomized men had significantly lower pro-alpha-C-RI levels than all other groups (P < 0.05). Inhibin A was undetectable in all men tested in this study. Six normal men who were administered exogenous levonorgestrel and testosterone had significantly lower serum gonadotropin, inhibin B, and pro-alpha-C-RI levels during the treatment period than the control and recovery periods (P < 0.05). Ten normal men who were administered human recombinant FSH had significantly higher peak serum FSH (21.85 +/- 3.23 IU/L vs. 3.01 +/- 0.51 IU/L), inhibin B (311 +/- 88 pg/mL vs. 151 +/- 23 pg/mL) and pro-alpha-C-RI (646 +/- 69 vs. 402 +/- 38 pg/mL) levels during the treatment period than the baseline values (P < 0.05). We conclude that inhibin B is a unique testicular product that is not detectable in the sera of orchidectomized men, is responsive to FSH stimulation, and has a reciprocal relationship with serum FSH levels in men with various forms of testicular disease. Therefore, inhibin B is likely to be the physiologically important form of inhibin in men.
我们采用一种最近开发的酶联免疫吸附测定(ELISA)方法来验证抑制素B是男性体内抑制素的生理活性形式这一假说。我们测定并比较了正常男性在促性腺激素水平受到干扰前后以及正常男性与患有下丘脑-垂体-睾丸轴各种紊乱疾病男性(包括特发性低促性腺激素性腺功能减退症男性、卵泡刺激素(FSH)升高的不育男性、克兰费尔特综合征男性以及睾丸切除男性)的基线值时,抑制素A、抑制素B和前α-C相关免疫反应性肽(pro-α-C-RI)的水平。正常男性的血清抑制素平均浓度显著高于未经治疗的特发性低促性腺激素性腺功能减退症男性、FSH升高的不育男性、未经治疗的克兰费尔特综合征男性以及睾丸切除男性(分别为187±28 vs 45±11、37±6、11±3和≤10 pg/mL;P<0.05)。所有睾丸切除男性的抑制素B水平均低于检测限。在所有研究对象(包括睾丸切除男性)中均可检测到pro-α-C-RI水平,除睾丸切除男性的pro-α-C-RI水平显著低于所有其他组(P<0.05)外,正常男性与患有各种睾丸疾病男性之间的pro-α-C-RI水平未发现显著差异。在本研究检测的所有男性中均未检测到抑制素A。6名接受外源性左炔诺孕酮和睾酮治疗的正常男性在治疗期间的血清促性腺激素、抑制素B和pro-α-C-RI水平显著低于对照期和恢复期(P<0.05)。10名接受重组人FSH治疗的正常男性在治疗期间的血清FSH峰值(21.85±3.23 IU/L vs. 3.01±0.51 IU/L)、抑制素B(311±88 pg/mL vs. 151±23 pg/mL)和pro-α-C-RI(646±69 vs. 402±38 pg/mL)水平均显著高于基线值(P<0.05)。我们得出结论,抑制素B是一种独特的睾丸产物,在睾丸切除男性的血清中无法检测到,对FSH刺激有反应,并且在患有各种形式睾丸疾病的男性中与血清FSH水平呈负相关。因此,抑制素B可能是男性体内抑制素的生理重要形式。